Image

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Exploring different treatments for advanced HR+/HER2- breast cancer.

Recruiting
18 years and older
All
Phase 3

This study is looking at a new treatment for certain types of breast cancer that cannot be surgically removed or have spread to other parts of the body. The study will test a medicine called *sacituzumab tirumotecan*, alone and with another medicine called *pembrolizumab*, against other treatments chosen by doctors. Sacituzumab tirumotecan is a medicine that targets cancer cells, while pembrolizumab helps the immune system fight cancer. The study aims to see if these medicines can stop cancer from growing longer than current treatments.

Participants need to have specific types of breast cancer that are hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-). They should have tried certain hormone treatments before and should be healthy enough to undergo chemotherapy.

  • The study will last for several months with regular visits.
  • Participants will receive either the study treatment or a treatment chosen by their doctor.
  • Potential side effects include those typical of cancer treatments, such as tiredness or infection risks.
Study details
    Breast Neoplasms

NCT06312176

Merck Sharp & Dohme LLC

8 March 2025

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

  Other languages supported:

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.